Quick access to up-to-date company information.
U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes
FDA and EMA accept regulatory applications for Boehringer Ingelheim’s Gilotrif® (afatinib) for treatment of advanced squamous cell carcinoma of the lung
Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
New Published Data Show STIOLTO™ RESPIMAT® Provides Clinically Meaningful Improvements in COPD Health-Related Quality of Life Measure
Boehringer Ingelheim and Circuit Therapeutics announce new collaboration to discover novel medicines for obesity
Click here to subscribe to email press release alerts
900 Ridgebury Rd. P.O. Box 368 Ridgefield, CT 06877